All In Biotech

Drug Trial Radar · NCT01387711

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

A Phase I, Single-centre, Open Label, Within-subject Comparison Trial to Explore the Biological Effects of PEP005 (Ingenol Mebutate) Gel, 0.05%, Applied Once Daily for 2 Consecutive Days in Patients With Actinic Keratosis on the Upper Extremity

Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Aug 2011

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jul 4, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by histology.

Conditions

  • Actinic Keratosis

Interventions

  • PEP005 (Ingenol mebutat Gel, 0.05 %)Drug

    All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Leukocytes Infiltration and degree of necrosis of the AK lesion and skinTime frame: From baseline until day 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitätsmedizin Göttingen, Georg-August-Universität

    Göttingen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.